← Eichor
Condition: Systemic Light Chain Amyloidosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Systemic Light Chain Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780Essen Amyloidosis Registry
Phase N/A · 1 location(s) · University Hospital, Essen · NCT06887283Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis
Phase 1/Phase 2 · 27 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07266116A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Phase 1 · 1 location(s) · University of Tennessee Graduate School of Medicine · NCT05951816Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
NA · 2 location(s) · Peking University People's Hospital · NCT06699394Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825The Italian Transthyretin Amyloidosis Web-Network
Phase N/A · 30 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT05444920Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07626476Daratumumab for Patients With Light Chain Amyloidosis
NA · 1 location(s) · Nanjing University School of Medicine · NCT063762143'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Phase 2 · 1 location(s) · Jin Lu, MD · NCT06342466The Impact of Systemic Light Chain Amyloidosis on Eyes
Phase N/A · 1 location(s) · Zhongshan Ophthalmic Center, Sun Yat-sen University · NCT06803082Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Phase N/A · 1 location(s) · Boston Medical Center · NCT00898235Hungarian National Systemic Amyloidosis Registry
Phase N/A · 12 location(s) · Semmelweis University · NCT07689331A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethaso
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07388602BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07151690Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Phase 2 · 3 location(s) · Peking University People's Hospital · NCT07335887Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NA · 7 location(s) · Jin Lu, MD · NCT06192979Rapid dFLC Response Predict CHR in AL Amyloidosis
Phase N/A · 8 location(s) · Peking University People's Hospital · NCT06627309
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.